The Online Investor
OKYO Pharma Ltd (OKYO)

OKYO Pharma is a preclinical biopharmaceutical company developing therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Co.'s research program is focused on a G Protein-Coupled Receptor. Co.'s preclinical product candidate, OK-101, is focused on keratoconjunctivitis sicca, commonly referred to as dry-eye disease (DED), which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. Co. has also been evaluating OK-201, a bovine adrenal medulla lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
Company Name: 
OKYO Pharma Ltd
Website: 
www.okyopharma.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree OKYO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

OKYO Pharma Ltd (OKYO) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.